Literature DB >> 2558750

Antiestrogen and antiandrogen administration reduce bone mass in the rat.

S Feldmann1, H W Minne, S Parvizi, M Pfeifer, U G Lempert, F Bauss, R Ziegler.   

Abstract

In mature female and male rats sex hormone deficiency was produced by surgical castration and by antiestrogen or antiandrogen administration. For the latter purpose we used the nonsteroidal antiestrogens tamoxifen, keoxifene (LY156758) and tetramethylhexestrol, and the steroidal antiandrogen cyproterone acetate. Dosages of 0.4 mg tamoxifen/rat/day and isomolar dosages of keoxifene and tetramethylhexestrol led to a bone mass reduction which was comparable to ovariectomized rats. Cyproterone acetate showed, at 10 mg/rat/day, a similar decrease in bone mass like orchidectomy. The often discussed intrinsic estrogen activity of the antiestrogens was present only in the highest dosage tested of tamoxifen. Keoxifene and tetramethylhexestrol showed no estrogenic effects, but this may be a dosage problem. Cyproterone acetate revealed no androgenic side-effects. These results indicate that antigonadal hormone drugs reduce bone mass to a varying extent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558750     DOI: 10.1016/0169-6009(89)90081-0

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  3 in total

1.  Ovarian status influences the skeletal effects of tamoxifen in adult rats.

Authors:  J D Sibonga; G L Evans; E R Hauck; N H Bell; R T Turner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen.

Authors:  J A Kalef-Ezra; N Pavlidis; G Klouvas; A Karantanas; I Hatzikonstantinou; D Glaros
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: preliminary study.

Authors:  W G Ryan; J Wolter; J D Bagdade
Journal:  Osteoporos Int       Date:  1991-10       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.